ALKS

Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021

Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting

Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference

Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved

Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med

Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder